DE1801390C3 - 6,9,21-trihalo steroids, processes for their preparation, medicaments containing them and 6,21-dihalo intermediates - Google Patents
6,9,21-trihalo steroids, processes for their preparation, medicaments containing them and 6,21-dihalo intermediatesInfo
- Publication number
- DE1801390C3 DE1801390C3 DE19681801390 DE1801390A DE1801390C3 DE 1801390 C3 DE1801390 C3 DE 1801390C3 DE 19681801390 DE19681801390 DE 19681801390 DE 1801390 A DE1801390 A DE 1801390A DE 1801390 C3 DE1801390 C3 DE 1801390C3
- Authority
- DE
- Germany
- Prior art keywords
- chlorine
- dione
- fluorine
- methyl
- steroids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000003431 steroids Chemical class 0.000 title claims description 5
- 239000003814 drug Substances 0.000 title claims 2
- 238000000034 method Methods 0.000 title claims 2
- 239000000543 intermediate Substances 0.000 title 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N HF Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 5
- 239000004593 Epoxy Substances 0.000 claims description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 4
- -1 halogen steroids Chemical class 0.000 claims description 4
- 229910000040 hydrogen fluoride Inorganic materials 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 235000011056 potassium acetate Nutrition 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 9
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 239000000460 chlorine Substances 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical group [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 125000003700 epoxy group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- VRLDVERQJMEPIF-UHFFFAOYSA-N DBDMH Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 claims 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N Succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002440 hydroxy compounds Chemical class 0.000 claims 1
- 229960002317 succinimide Drugs 0.000 claims 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 5
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 4
- 239000000155 melt Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000005457 ice water Substances 0.000 description 3
- 208000005679 Eczema Diseases 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M Lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 201000004624 dermatitis Diseases 0.000 description 2
- 231100001003 eczema Toxicity 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010003246 Arthritis Diseases 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 208000010247 Contact Dermatitis Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000004559 Hearing Loss Diseases 0.000 description 1
- 206010011879 Hearing loss Diseases 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229960003975 Potassium Drugs 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M Potassium bicarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001396 anti-anti-diuretic Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- TXHIDIHEXDFONW-UHFFFAOYSA-N benzene;propan-2-one Chemical compound CC(C)=O.C1=CC=CC=C1 TXHIDIHEXDFONW-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 231100000080 dermatitis contact Toxicity 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000001882 diuretic Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 201000009053 neurodermatitis Diseases 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical class OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Description
18 Oi18 Oi
m die I I1' OH l)\ 1 ■luo.gi uppieiuiu· umgewandelt wild.m the II 1 'OH l ) \ 1 ■ luo.gi uppieiuiu · converted wild.
Die criinduugsgenuLien neuen M.2! 1 iih.iloucnsieroide der angegebenen allgemeinen Found I /eichnen sich durch hohe entzündungshemmende Wnkuiii: .ms. wie in der nachfolgenden l'alvlle .im Bespiel des ertindungsgemälk-n tw-l-'Unn-·1»»,Γ1 - Jit-hliM1-1 I.Mn dro\ > -16.V- methyl- 1.4 -pregnadien ',20-diou (hl im Vergleich /um bekannten tu-Fluoi I l.>'.2l-dilndui\\- lru-meth>l-i.4-pregnadien-3,20-dion |ai ausweist. Dabei wurde die Wirkungsintensität nach dem bekannten Vasokonstriktionsiest. wobei geringe, mittlere und hochgradige Yasokonstriktion /wischen I) und ItX) bewerte', wurde, an gebunden männlichen Versuchspersonen im Alter von 18 bis 38 Jahren bestimmt Her Wirkstoff wurde in einer Wasser-Öl-Salbingrunulage. wobei die konzentration 0.01.0.001 und 0.UH)I''α betrug, appli/iert.The criinduugsgenuLien new M.2! 1 iih.iloucnsieroide of the specified general Found I / are characterized by high anti-inflammatory Wnkuiii: .ms. as in the following l'alvlle. in the example of the invention-n tw-l-'Unn- · 1 »», Γ1 - Jit-hliM 1 -1 I.Mn dro \> -16.V- methyl- 1.4 -pregnadiene ', 20-diou (hl in comparison / around the well-known tu-fluoi I l.>'. 2l-dilndui \\ - lru-meth> li.4-pregnadien-3,20-dione | ai according to the known vasoconstriction test, where low, medium and high-grade yasoconstriction / wipe I) and ItX) was assessed on bound male test persons aged 18 to 38 years. Her active ingredient was determined in a water-oil anointing runage. where the concentration was 0.01.0.001 and 0.UH) I''α, applied.
Bcob.ithliin^.-ii m StundenBcob.ithliin ^ .- ii m hours
ι : ϊ 4ι: ϊ 4
ο χ-!- luor-U..,2l-dih> dl oxvl tu- meilnl-1.4-pregnadien-3,20-dion ο χ -! - luor-U .., 2l-dih> dl oxvl tumeilnl-1.4-pregnadiene-3,20-dione
! ,4-pregnadiei!-3.2t)-(.lii.>[t! , 4-pregnadiei! -3.2t) - (. Lii.> [T
'-h\dio\>-lax-meth>l-'-h \ dio \> - lax-meth> l-
90 10090 100
Die Versuchsergebnisse /eigen, daIi die ertiiuluiiLZsgemäßen
6.9.21-Trihalogensteroide gegenüber der bekannten
Substanz a) in allen Dosisbereichen eine deutlich höhere Wirkungsintensität besitzen Darüber
hinaus sind sie durch einen früheren Wirkungsbeginn ausgezeichnet und erreichen auch ihr Wirkungsmaximum
schneller. Die Verbindungen rufen keine Natriumretention hervor. Sie besitzen leichte diuretische
Wirkungen. Die neuen Verbindungen sind in Kombination mit den in der galenischen Pharmazie
üblichen Träger- und Verdünnungsmitteln
gut geeignet zur Behandlung von z. U.The test results / own that the certified 6.9.21-trihalogensteroids have a significantly higher intensity of action compared to the known substance a) in all dose ranges. The compounds do not cause sodium retention. They have mild diuretic effects. The new compounds are in combination with the usual in galenic pharmacy carriers and diluents
well suited for the treatment of z. U.
a) lokal: Kontaktdermatitis, F.kzeme der verschiedensten Art. Neurodermatitis, Hrvihroderniie, Verbrennungen, Pruritus vulvae et aiii, Rosacea, F.rwhematodes cutaneus. Psoriasis. Liehen ruber planus verrucüsus:a) locally: contact dermatitis, various kinds of eczema Art. Neurodermatitis, hearing loss, burns, Pruritus vulvae et aiii, Rosacea, F.rwhematodes cutaneus. Psoriasis. Liehen ruber planus verrucüsus:
b) oral: akute und chronische Polyarthritis. Neurodermitis. Asthma bronchiale, Heutieber u.a.b) oral: acute and chronic polyarthritis. Eczema. Bronchial asthma, Heutieber et al.
Die zur Herstellung der 6,9,21-Trihalogensteroide benutzten Ausgangsprodukte der allgemeinen Formel 1! sind ebenfalls nicht vorbeschrieben. Sie können beispielsweise aus dem bekannten (n-Fluor-21-acet-OXV-16λ-methyl-1.4,9(1 l)-pregnatrien-3,20-dion nach an sich bekannten Arbeitsmethoden hergestellt werden: durch Verseifen der 21-Acyloxygruppe, z.B. in Methanol/Methylenchlorid mit Kaliumhydroxyd bei 0 bis 5 C unter Ausbildung des 21-Alkohols (F. 190 bis 192 C) und erneuter Veresterung der frei gewordenen 21-Hydroxylgruppe mit Sulfochloriden, z.B. Methansulfonsäurechlorid. in Pyridin bei 0 bis 5 C erhält man zunächst ax-Fluor-21-mesylo\y-16A-rnethyl-l,4,9(ll)-pregnairien-3.?0-dion(F. 149 bis 150 C). Die 21-Mesyloxygruppe wird schließlich in z. B. Dimethylformamid vorzugsweise bei erhöhter Temperatur durch das letztlich gewünschte Halogenatom ausgetauscht: mit z. B. Kaliumhydrogenfiuorid erhält man die entsprechende 21-Fluorverbindung. mit Lithiumchlorid die entsprechende 21-Chlorverbindung. Die 21-Chlorverbindung ist aber auch aus dem 2!-Alkohol (F. 190 bis 192 C) durch Behandlung mit Thionylchlorid in Pyridin herstellbar.The ones used to make the 6,9,21-trihalogen steroids used starting products of the general formula 1! are also not described above. You can for example from the well-known (n-fluoro-21-acet-OXV-16λ-methyl-1.4,9 (1 l) -pregnatriene-3,20-dione can be produced according to working methods known per se: by saponifying the 21-acyloxy group, e.g. in Methanol / methylene chloride with potassium hydroxide at 0 to 5 C with formation of the 21-alcohol (F. 190 up to 192 C) and re-esterification of the released 21-hydroxyl group with sulfochlorides, e.g. Methanesulfonic acid chloride. in pyridine at 0 to 5 ° C one obtains first ax-fluoro-21-mesylo \ y-16A-methyl-1,4,9 (ll) -pregnairien-3,? 0 -dione (F. 149 to 150 C). The 21-mesyloxy group is finally used in e.g. B. Dimethylformamide, preferably at an elevated temperature, through the halogen atom ultimately desired exchanged: with z. B. Kaliumhydrogenfiuorid one receives the corresponding 21-fluorine compound. with lithium chloride the corresponding 21-chloro compound. The 21-chlorine compound is also from the 2! -Alcohol (mp 190 to 192 C) can be prepared by treatment with thionyl chloride in pyridine.
Die nachfolgenden Beispiele dienen der weiteren Erläuterung der vorliegenden Erfindung.The following examples serve to further illustrate the present invention.
45 Ϊ45 Ϊ
5.5g h\-Fluor-2!-chlor-16\-meth\l-l,4.9| I l)-pregnatrien"-3.20-dion (F. 2OS bis 209 C)* werden in HX) ml Tetrahydrofuran gelöst, mit 5.5 g N-Chlorsuccinimid und 44 ml 1 n-Perchlorsäure versetzt und 21 , Stunden bei 35 C gerührt. Die Reaktionslösung wird in Eiswasser eingegossen, die ausgefallene Substanz abgesaugt, neutral gewaschen und getrocknet. Das so erhaltene 6A-Fluor-9.2I-dichlor-l 1 ,^-hydroxy-16\-meth\!-1.4-pregnadien-3.20-dion wird aus Aceton-Hexan umkristallisiert: F. 233 bis 235 C: Ausbeute 90° u der Theorie: UV: f;JS = 15 SOO.5.5gh \ -Fluor-2! -Chlor-16 \ -meth \ ll, 4.9 | I l) -pregnatriene "-3.20-dione (F. 2OS to 209 C) * is dissolved in HX) ml of tetrahydrofuran with 5.5 g of N-chlorosuccinimide and added 44 ml of 1 N perchloric acid and 2 1, stirred for hours at 35 C The reaction solution is poured into ice water, the precipitated substance is filtered off with suction, washed neutral and dried. The 6A-fluoro-9.2I-dichloro-l 1, ^ - hydroxy-16 \ -meth \! Dione is recrystallized from acetone-hexane: mp 233 to 235 C: yield 90 ° u of theory: UV: f; JS = 15 SOO.
7 g 6\-Fluor-21 -chlor-1 tn-methyl-1.4,9111 l-pregnatrien-3.20-dion werden in 150 ml Tetrahydrofuran gelöst, mit 10.5 g N-Bromsuceinimid und 65 ml In-Perchlorsäure versetzt und 15 Minuten bei 35 C gerührt. Die Reaktionslösung wird in Eiswasser eingegossen. Natriumsulfit zugesetzt und 30 Minuten gerührt. Die ausgefallene Substanz wird abgesaugt, neutral gewaschen und getrocknet. Nach Umkristallisation aus Aceton-Hexan werden 6.9 g 6x-Fluor-21 -chlor-9-brom-11/i'-hydroxy- 16λ-methyl- 1.4-pregnadien-3.20-dion erhalten: F. 218 C (Zers.l: UV: rui = 14 5(X). 7 g of 6-fluorine-21-chloro-1 tn-methyl-1.4,9111 l-pregnatriene-3.20-dione are dissolved in 150 ml of tetrahydrofuran, mixed with 10.5 g of N-bromosuceinimide and 65 ml of in-perchloric acid and added for 15 minutes 35 C stirred. The reaction solution is poured into ice water. Sodium sulfite was added and the mixture was stirred for 30 minutes. The precipitated substance is filtered off with suction, washed neutral and dried. After recrystallization from acetone-hexane, 6.9 g of 6x-fluoro-21-chloro-9-bromo-11 / i'-hydroxy-16λ-methyl-1,4-pregnadiene-3.20-dione are obtained: F. 218 C (decomp. 1: UV: r ui = 14 5 (X).
S.6 g 6\-Fluor-21-chlor-9-broni-l l;)-h\droxy-I6\-meth\l-1.4-pregnadien-3.20-dion werden in 160 ml Äthanol und 40 ml Tetrahvdrofuran mit 16 g Kaliumacetat 45 Minuten unter Rückfluß erhitzt. Das Reaktionsgemisch wird in Eiswasser eingerührt, der ausgefallene Niederschlag abgesaugt, mit Wasser gewaschen und getrocknet. Das isolierte Rohprodukt wird an Silicagel Chromatographien. Durch Eluieren mit Hexan Aceton-Gemischen wird das 6\-Huor-2l-chlor-9.11()' - epoxy - 16\ - methyl - 9,τ' - pregna - 1.4 - dien-3.20-dion erhalten; F. 139 bis 139.5 C(fsoprop\läther); UV: f:iS = 15S(X).6 g of 6-fluorine-21-chloro-9-broni-1 l;) - hydroxy-16-meth \ l-1,4-pregnadiene-3.20-dione are mixed with 160 ml of ethanol and 40 ml of tetrahydrofuran 16 g of potassium acetate heated under reflux for 45 minutes. The reaction mixture is stirred into ice water, and the precipitate which has separated out is filtered off with suction, washed with water and dried. The isolated crude product is chromatographed on silica gel. By eluting with hexane-acetone mixtures, the 6 \ -Huor-2l-chloro-9.11 ( ) '- epoxy - 16 \ - methyl - 9, τ' - pregna - 1.4 - diene-3.20-dione is obtained; F. 139 to 139.5 C (isopropyl ether); UV: f: iS = 15S (X).
15 ml Dimethylformamid werden auf —15 C gekühlt und mit 15 ml Fluorwasserstoff unter Rühren15 ml of dimethylformamide are cooled to -15 ° C and with 15 ml of hydrogen fluoride with stirring
18 Ol18 Ol
versetzt. Zu dieser Mischung werden 3,15 g (n-Fluor-2! - chlor - 9,11/i - epoxy - Ι6λ - methyl - 9/>' - pregnal,4dien-3,20-dion gelöst in 5 ml Dimethylformamid zugelropfl und 18 Stunden bei 5 C und 9 Stunden hei 20 C stehengelassen. Die Reüklionsltfsung wird in Kiswasser/Kaliumhydrogencarbonal eingegossen, die dabei ausgefallene Substanz abgesaugt, getrocknet und aus Accton/Hcxan umkrislallisiert. Das se erhaltene 6v9-Difluor-21 -chlor- 11//-hydroxy- Un-methyll.4-pre^nadien-3,20-dion schmilzt bei 215 bis 216 C \o (Zers.);lJV:,,iH - 16 200; Ausbeute 80% der Theorie.offset. 3.15 g of (n-fluoro-2! - chloro - 9.11 / i - epoxy - Ι6λ - methyl - 9 />'- pregnal, 4diene-3,20-dione dissolved in 5 ml of dimethylformamide are added dropwise to this mixture and left to stand for 18 hours at 5 ° C. and 9 hours at 20 ° C. The reaction solution is poured into cold water / potassium hydrogen carbonate, the substance which has precipitated is suctioned off, dried and recrystallized from acetone / hydrogen. / Un-hydroxy- methyll.4 pre-^ Nadien-3,20-dione melts at 215-216 C \ o (dec.); LJV: iH ,, - 16 200; yield 80% of theory.
3 g 6\-21-Difluor-16\-methy1-1,4.9(1 l)-pregnalrien-3,20-dion (F. 229 bis 231 C) werden in 70 ml Tetra- ;s hydrofuran mit 3 g N-Chlorsuccinimid und 24 ml 1 n-Perchlorsäure umgesetzt und aufgearbeitet, wie im Beispiel 1 beschrieben. Das so e-haltene 6\,21-Difluor - 9 - chlor -1J β - hydroxy -16\ - methyl -1,4 - pregnadien-3,20-dion schmilzt nach Umkristallisation aus Aceton-Bcnzol bei 255 bis 256 C: LJV: ,2,K = 15 900; Ausbeute 65% der Theorie.3 g 6 \ -21-difluoro-16 \ -methy1-1,4.9 (1 l) -pregnalrien-3,20-dione (temperature 229 to 231 C) are mixed with 3 g of N in 70 ml of tetrahydrofuran -Chlorsuccinimide and 24 ml of 1 n-perchloric acid reacted and worked up as described in Example 1. The 6, 21-difluoro-9-chloro-1- β -hydroxy-16-methyl-1,4-pregnadiene-3,20-dione thus obtained melts after recrystallization from acetone-benzene at 255 to 256 C: LJV:, 2 , K = 15,900; Yield 65% of theory.
9.8 g 6x,21-Dinuor-16.\-mcthyl-!.4.9(ll)-prcgnatrien-3.20-dion werden in 210 ml Tetrahydrofuran mit 14 7 g N-ßromsuecinimid und 9ImI I η■ I1Uichlorsäure 10 Minuten bei 35 C gerührt und aufgearbeitet, wie im Beispiel 2 beschrieben. Das so erhaltene 6λ.2Ι - Difliior-9-brom- I !//-hydroxy- Km -meilisl-I 4-pregnadien-3.20-dion wird aus Aceton umkristallisiert: F. 210 C (Zers.l; Ausbeute 98% der Theorie9.8 g 6x, 21-Dinuor-16 \ -. Mcthyl - !. 4.9 (II) -prcgnatrien-3,20-dione in 210 ml of tetrahydrofuran with 14 g of N-7 and ßromsuecinimid 9ImI I η ■ I 1 Uichlorsäure 10 minutes at 35 C stirred and worked up as described in Example 2. The 6λ.2Ι - difliior-9-bromo-I! // - hydroxy-Km -meilisl-I 4-pregnadiene-3.20-dione obtained in this way is recrystallized from acetone: mp 210 ° C. (decomp. 1; yield 98% of the theory
10 g 6\,21-Diiluor-9-brom-l I/(-hydroxy-l(S\-methyl-l,4-pregnadien-3,20-dion werden in 250 ml Äthanol und 100 ml Tetrahydrofuran mit 20 g wasserfreiem Kaliumacetal umgesetzt, 60 Minuten unter Rückfluß erhitzt und aufgearbeitet, wie im Beispiel 3 beschrieben. Das so erhaltene 6^,21-Difluor-9.1 i/i-epoxy-Kn-methyl-9//-pregnal,4-dien-3,20-dion schmilzt bei 177 bis 179 C; Ausbeute 92% der Theorie.10 g 6 \, 21-Diiluor-9-bromo-l I / (- hydroxy-l (S \ -methyl-1,4-pregnadiene-3,20-dione are in 250 ml of ethanol and 100 ml of tetrahydrofuran with 20 g of anhydrous Potassium acetal reacted, heated under reflux for 60 minutes and worked up as described in Example 3. The 6 ^, 21-difluoro-9.1 i / i-epoxy-Kn-methyl-9 // - pregnal, 4-diene-3,20-dione obtained in this way melts at 177 to 179 C; Yield 92% of theory.
7.6 g 6v21 -Difluor-9,11 //-epoxy-16>-mcthyl-9//-pregna-1.4-dicn-3,20-dion werden bei -20 C in eine Mischung von 40 ml Dimethylformamid und 40 ml * Fluorwasserstoff eingetragen und 24 Stunden bei Raumtemperatur gerührt. Die Aufarbeitung des Reaktionsgemisches erfolgte wie im Beispiel 3 beschrieben. Das so erhaltene 6^9,2l-Trifluor-11//-hydroxy-16\- methy1-l,4-pregnadien-3,2()-dion wird aus Aceton Hexan umkristallisiert und schmilzt bei 287 bis 289 C unter Zersetzung; Ausbeute 80% der Theorie.7.6 g 6v21 -difluoro-9.11 //-epoxy-16>-methyl-9//-pregna-1.4-dicn-3,20-dione are at -20 C in a mixture of 40 ml of dimethylformamide and 40 ml * Entered hydrogen fluoride and stirred for 24 hours at room temperature. Working up the reaction mixture took place as described in Example 3. The 6 ^ 9,2l-trifluoro-11 // - hydroxy-16 \ - thus obtained Methy1-1,4-pregnadiene-3,2 () - dione is recrystallized from acetone hexane and melts at 287 to 289 ° C with decomposition; Yield 80% of theory.
Claims (6)
CII-. Y1. 6,9,21-trihalosteroids of the formula
CII-. Y
maß Anspruch I.7th
measure claim I.
wherein X is a fluorine, chlorine or bromine atom and Y is a chlorine or fluorine atom.
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19681801390 DE1801390C3 (en) | 1968-10-02 | 6,9,21-trihalo steroids, processes for their preparation, medicaments containing them and 6,21-dihalo intermediates | |
RO61035A RO54664A (en) | 1968-10-02 | 1969-09-15 | |
IL33017A IL33017A (en) | 1968-10-02 | 1969-09-17 | 6alpha9alpha,21-trihalo-11beta-hydroxy-16alpha-methyl-pregna-1,4-diene-3,20-diones |
CH1427369A CH540891A (en) | 1968-10-02 | 1969-09-22 | Process for the preparation of 6,9,21-trihalosteroids |
GB48004/69A GB1286659A (en) | 1968-10-02 | 1969-09-30 | 6,9,21-trihalogenosteroids |
ES372061A ES372061A1 (en) | 1968-10-02 | 1969-09-30 | 6,9,21-trihalogenosteroids |
IE1363/69A IE33329B1 (en) | 1968-10-02 | 1969-09-30 | 6,9,21-trihalogenosteroids |
CS6578A CS150285B2 (en) | 1968-10-02 | 1969-10-01 | |
NO3902/69A NO130824C (en) | 1968-10-02 | 1969-10-01 | |
SE13534/69A SE352082B (en) | 1968-10-02 | 1969-10-01 | |
FR6933482A FR2019676A1 (en) | 1968-10-02 | 1969-10-01 | |
DK523169AA DK121053B (en) | 1968-10-02 | 1969-10-01 | Analogous process for the preparation of therapeutically active 6α, 9α, 21-trihalogen-16α-methyl-11β-hydroxy-1,4-pregnadiene-3,20-diones. |
AT928069A AT290033B (en) | 1968-10-02 | 1969-10-01 | Process for the preparation of new 6,9,21-trihalogen steroids |
BR212959/69A BR6912959D0 (en) | 1968-10-02 | 1969-10-02 | PROCESS FOR THE PREPARATION OF 6 9 21-TRIHALOGENO STEROIDS |
FI692843A FI46505C (en) | 1968-10-02 | 1969-10-02 | Process for the preparation of therapeutically useful 6alpha, 9alpha, 2-trihalogen-16alpha-methyl-11beta-hydroxy-1,4-pregnadiene-3,20-diones. |
BE739736D BE739736A (en) | 1968-10-02 | 1969-10-02 | |
NL6914942.A NL167439C (en) | 1968-10-02 | 1969-10-02 | PROCESS FOR THE PREPARATION OF 16-Alpha-METHYL-6,9,21-TRIHALOGENIC STATES WITH ANTI-INFLAMMATORY EFFECT, PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL AND PREPARED PHARMACEUTICAL PREPARATION. |
US00259819A US3819604A (en) | 1968-10-02 | 1972-06-05 | 6,9,21-trihalogenosteroids |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19681801390 DE1801390C3 (en) | 1968-10-02 | 6,9,21-trihalo steroids, processes for their preparation, medicaments containing them and 6,21-dihalo intermediates |
Publications (3)
Publication Number | Publication Date |
---|---|
DE1801390A1 DE1801390A1 (en) | 1970-05-21 |
DE1801390B2 DE1801390B2 (en) | 1977-02-17 |
DE1801390C3 true DE1801390C3 (en) | 1977-10-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE1568951A1 (en) | Process for the preparation of steroid [17alpha, 16alphad] oxazolines | |
DE1801390C3 (en) | 6,9,21-trihalo steroids, processes for their preparation, medicaments containing them and 6,21-dihalo intermediates | |
DE2645104A1 (en) | NEW CORTICOIDS | |
DE1801390B2 (en) | 6,9,21-TRIHALOGENE STEROIDS, PROCESS FOR THEIR MANUFACTURE, MEDICATIONS CONTAINING THEM AND 6,21-DIHALOGENE INTERMEDIATE PRODUCTS | |
DE3126942C2 (en) | ||
DE1932180A1 (en) | New halogenated steroids and their manufacture | |
DE2004767C3 (en) | Halogen steroids, processes for their production and pharmaceuticals containing them | |
AT249865B (en) | Process for the preparation of new pyrazole compounds of the pregnane series | |
DE2630270A1 (en) | 21-ACETALS AND MIXED 21-ACETALS OF STEROID-21-ALDEHYDE, INTERMEDIATE PRODUCTS AND METHOD FOR MANUFACTURING THE SAME | |
DE2433178A1 (en) | PREGNAN SERIES ALKYLATED STEROIDS IN THE 21 POSITION | |
AT232654B (en) | Process for the preparation of 16α-methyl-17α-hydroxy-20-ketones of the allopregnan series | |
AT232653B (en) | Process for the preparation of 16α-methyl-allopregnanes substituted in the 21-position | |
DE1921398C3 (en) | 2-chloro-3-oxo-1,4-pregnadienes, processes for their preparation and medicinal products containing them | |
DE2021718A1 (en) | New steroidal 21-aether derivatives and processes for their preparation | |
DE1493318C (en) | 3 beta, 17 alpha dihydroxy 6 alpha methyl 4 pregnen 20 on 3 sodium succinate 17 acetate and 3beta, 17 alpha dihydroxy 6 methyl 16 methylene 4,6 pregnadiene 20 on 3 sodium succinate 17 acetate and processes for the production of these compounds | |
AT333992B (en) | PROCESS FOR MANUFACTURING NEW D-HOMO STEROIDS OF THE PREGNAN SERIES | |
DE1807980C3 (en) | Process for the production of new halogen pregnadienes | |
DE1493344B1 (en) | Process for the preparation of 16 alpha-chloro- or -fluoro-17 (20) -pregnen-21-acid esters and 16 alpha-chloro- or -fluoro-17 alpha-hydroxy-20-keto-21-acyloxy compounds of the pregnane series obtainable therefrom | |
AT220764B (en) | Process for the preparation of new 3-oxo-Δ <1,4> -6-methyl- and 3-oxo-Δ <1,4,6> -6-methyl steroids | |
DE2226067C3 (en) | Process for the preparation of 16beta-methyl-17alpha-hydroxy-1,4,9 (11) pregnatriene-3,20-dione (1) | |
AT253706B (en) | Process for the preparation of 6-halo-1α, 2α-methylene-16α-methyl-Δ <4, 6> -pregnadien-17α-ol-3, 20-diones and their 17-esters | |
AT364098B (en) | METHOD FOR PRODUCING NEW ESTERS OF ANDROSTADIEN-17-CARBONIC ACIDS | |
CH495969A (en) | Delta1 4-16alpha-methyl-steroids | |
DE1075606B (en) | Process for the production of halogenated 4,6 pregnadiene-3-keto steroids | |
CH403754A (en) | Process for the preparation of 9 (11) -16a-methyl-21-acetoxy-allopregnen-3,20-dione |